Clinical trial
A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative…
NCT04004611 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT04004611 |
|---|---|
| Title | A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC) |
| Official title | A Multicenter, Open-Label PK Study of Mirikizumab in Pediatric Patients With Moderately to Severely Active Ulcerative Colitis |
| Acronym | SHINE-1 |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ulcerative Colitis |
| Intervention type | Drug |
| Interventions | Mirikizumab |
| Enrollment | 26 |
| Start date | May 18, 2020 |
| Primary completion | Mar 15, 2023 |
| Completion | Mar 15, 2023 |
| First posted | Jul 2, 2019 |
| Last update posted | Mar 26, 2024 |
| Countries | Canada, Israel, Japan, South Korea, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: